top of page

iQure Pharma’s iQ-007 Passes Cardiac Safety Test–Critical Milestone for GLP Toxicology Studies

Princeton, NJ, June 27, 2023 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has achieved another milestone towards IND by passing a significant cardiac safety test with iQ-007, their signature novel anti-convulsant compound.


iQure is pleased to announce that the specific affinity of iQ-007 towards the cardiac-selective binding channels, Nav1.5, Cav1.2 and hERG, were tested, and no binding was detected compared to the active reference compounds. Many anti-epileptic drugs have the potential for cardiac side effects, so it is crucial to eliminate this risk in the early stages of development. The latest results are in line with previous tests on non-selective sodium and calcium channels, which already proved negative. This shows once again the highly selective mechanism of iQ-007 as a positive allosteric modulator of the EAAT2 transporter.


"Cardiac safety is very important for a prospective medication like iQ-007, which is intended for mid- and long-term use. Here at iQure, we are mindful of how important quality of life is for patients and their families,” said iQure Chief Executive Officer, Pawel Zolnierczyk. “With these results, we can continue our efforts to advance iQ-007 to clinical trials, and ultimately offer patients an effective and safe therapy.”


About iQure Pharma

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO, Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.


35 views

Recent Posts

See All
bottom of page